AlphAIAlphAI — Financial news for AI agents
seekingalpha.comAUG 261 min read$ARGX

Argenx stock upgraded at UBS on Vyvgart (ARGX:NASDAQ)

UBS upgraded argenx SE (ARGX) to Buy from Neutral, raising its 12-month price target to $1,400 from $960. The firm projects a $20B peak sales opportunity for the company's flagship product, Vyvgart.

Original reporting
seekingalpha.com
Published Aug 26, 2026, 1:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$ARGX
Bullish
high confidence
Mentioned
$ARGX
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ARGXBullishHigh
01

Why it matters

The upgrade could attract new buying pressure and lift the stock toward the new target price.

02

Market read

Analyst upgrades are a common catalyst for short‑term price moves in biotech stocks.

03

What to watch

Potential regulatory or competitive risks for Vyvgart not addressed in the upgrade.

Relevance 7/10Novelty 8/10Timing: today

Background

Argenx SE (ARGX) is a Dutch biotech company focused on rare diseases, with Vyvgart as its lead product.

Company-level read

Ticker impact

$ARGXBullishHigh confidence
Context

UBS upgraded Argenx to Buy and raised the 12‑month price target to $1,400 from $960.

Expected impact

Potential price increase as investors price in higher target.

Evidence & confidence

Upgrade and higher target are fresh, primary information that can drive buying interest.

Market effects

Sector

Boosts sentiment for the biotech/rare‑disease sector.

Regional

Limited to US and European biotech investors.

Global

Minor global impact, primarily affects biotech equities.

Counterpoint

What could challenge this read

Upgrade may be premature if sales forecasts for Vyvgart are overly optimistic.

Key entities

  • Analyst
    UBS

    Equity research firm providing the upgrade and new price target.

  • Product
    Vyvgart

    Flagship drug expected to generate up to $20B in peak sales.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 2
$ARGXMedAI 8/10

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth

Argenx (NASDAQ: ARGX) reported 18 consecutive quarters of revenue growth, with Q2 2026 sales up 60% YoY. Its Vyvgart therapies are driving growth, and the company expects multiple pivotal clinical results through 2027. Analysts rate it a buy with a 14% upside. Argenx's stock has more than doubled in three years.

aol.com3 min
AUG 28
$ARGXHighAI 8/10

argenx (ENXTBR:ARGX) Just Gave Investors Something To Think About

argenx (ARGX) reported positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. Shares have surged, with a 1-year return of 50.58%. Analysts debate valuation, with some calling it 32.2% overvalued at €907.40, while others see a 52.2% discount. Investors should watch for clinical setbacks and pricing pressures.

finance.yahoo.com2 min
AUG 26
$ARGXHigh

UBS Just Upgraded Argenx Stock. Here's Why.

UBS upgraded Argenx (ARGX) to 'Buy' with a $1,400 price target, citing strong Vyvgart franchise prospects and potential $20B peak sales. ARGX shares are up over 50% YTD. UBS also noted the company's expanding pipeline, including empasiprubart, addressing concerns about reliance on Vyvgart.

barchart.com2 min
AUG 26
$ARGXHigh

ARGX Looks 29.0% Undervalued on GF Value™

UBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.

gurufocus.com2 min